Akebia Therapeutics, Inc. (AKBA)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Akebia Therapeutics, Inc. currently loses $39.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Akebia Therapeutics’ revenue missed expectations in the third fiscal quarter of 2026, with results reported November 5, 2026, as revenue of $36.9 million trailed the $46.9 million estimate (-21.4%) and fell 37% year over year from $58.8 million. Adjusted EPS was -$0.040, down from $0.002 a year ago, as the company posted a net loss of roughly $14.4 million versus net income of $540,000.00 a year earlier. Profitability remained centered in gross profit of about $30.5 million, translating to a gross margin of roughly 83%, while operating results were pressured with operating income of around -$11.5 million and an operating margin of about -31%. Despite the net loss, Akebia generated operating cash flow of about $2.3 million for the quarter. Consensus for the next period calls for EPS of -$0.040 on revenue of $48.2 million.
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. is a biotechnology company focused on discovering and commercializing therapies for kidney diseases. Listed on the NASDAQ Global Market under AKBA, it sells and develops treatments for chronic kidney disease complications and generated $236.2 million of revenue in FY2025.
Today's Snapshot
AKBA closed 5.5% lower at 0.40, while its sector was flat. Akebia Therapeutics reported a third-quarter revenue miss, leading analysts to cut their price targets.
Trading Volume
Below 10d avg (5.9M)
4.1M
vs S&P 500 Today
Underperforming Market
-2.03%
Updated: November 20, 2026 at 21:19 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$0.46 - $1.05Sell
- RSI (14)33.48Neutral
- Stochastic %K (14, 3, 3)12.46Buy
- MACD Level (12, 26)-0.09Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.